There were 1,685 press releases posted in the last 24 hours and 414,162 in the last 365 days.

CLASS ACTION UPDATE for YRCW, IMMU, MKL and MAXR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

YRC Worldwide Inc. (NASDAQGS: YRCW)
Class Period:
March 10, 2014 - December 14, 2018
Lead Plaintiff Deadline: March 4, 2019
Join the action: https://www.zlk.com/pslra-1/yrc-worldwide-inc-loss-form?wire=3

About the lawsuit: During the class period, YRC Worldwide Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) from 2005 to at least 2013, YRC's units systematically overcharged the federal government for freight carrier services; (2) this alleged misconduct caused the Department of Defense to overpay by millions of dollars for shipments that were lighter, and thus cheaper, than the weights for which the government was charged; (3) consequently, this alleged misconduct would subject YRC to enhanced government scrutiny and liabilities, including potentially owing treble damages under the False Claims Act; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

To learn more about the YRC Worldwide Inc. class action contact jlevi@levikorsinsky.com.

Immunomedics, Inc. (NASDAQ: IMMU)
Class Period:
February 8, 2018 - January 18, 2019
Lead Plaintiff Deadline: February 25, 2019
Join the action: https://www.zlk.com/pslra-1/immunomedics-inc-loss-form?wire=3

About the lawsuit: Immunomedics, Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (i) Immunomedics’ Morris Plains, New Jersey drug substance manufacturing facility was not in compliance with FDA requirements; (ii) the Company’s Quality Control Unit did not possess the  authority to investigate and correct critical FDA violations occurring  at  the  Morris Plains, New Jersey facility; (iii) the Company suffered a February 2018 data integrity breach at the Morris Plains, New Jersey facility which, among other issues, included the backdating records and manipulation of bioburden samples; (iv) the Company’s Chemistry, Manufacturing and Control data submitted in connection with its BLA for sacituzumab govitecan was insufficient to support FDA approval; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

To learn more about the Immunomedics, Inc. class action contact jlevi@levikorsinsky.com.

Markel Corporation (NYSE: MKL)
Class Period:
July 26, 2017 - December 6, 2018
Lead Plaintiff Deadline: March 12, 2019
Join the action: https://www.zlk.com/pslra-1/markel-corporation-loss-form?wire=3

About the lawsuit: Markel Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s subsidiaries did not appropriately record loss reserves; (2) as a result, the loss reserves would need to be adjusted and/or restated; (3) these misleading accounting practices would lead to regulatory scrutiny and financial loss to investors; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

To learn more about the Markel Corporation class action contact jlevi@levikorsinsky.com.

Maxar Technologies Inc. (NYSE: MAXR)
Class Period:
March 29, 2018 - January 7, 2019
Lead Plaintiff Deadline: March 15, 2019
Join the action: https://www.zlk.com/pslra-1/maxar-technologies-inc-loss-form?wire=3 

About the lawsuit: During the class period, Maxar Technologies Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Maxar improperly inflated the value of its intangible assets, among other accounting improprieties; (ii) Maxar’s highly-valued WorldView-4 was equipped with CMGs that were faulty and/or ill-suited for their designed and intended purpose; and (iii) as a result, Maxar’s public statements were materially false and misleading at all relevant times.

To learn more about the Maxar Technologies Inc. class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

 

250x148_zlk.jpg